Micellular Water Regimen Found to Improve Redness, Quality of Life in Centrofacial Erythema

Woman wakes from sleep and she was cleansing the morning before shower
Skin redness and other symptoms associated with rosacea were found to improve with the use of a skincare regimen formulated for the treatment of centrofacial erythema.

 Skin redness and other symptoms associated with rosacea were found to improve with the use of a skincare regimen formulated for the treatment of centrofacial erythema, according to study findings published in the Journal of Cosmetic Dermatology.

In this study, the effectiveness of a skincare regimen — consisting of micellar water, cream, and serum, designed for sensitive and redness-prone skin — on facial erythema and other rosacea-associated symptoms including itching, tension, warmth, burning, and dryness, was examined.

A total of 60 Caucasian patients with centrofacial erythema were enrolled in this single-center, 8-week, prospective, randomized trial (n=50 in the intervention group; n=10 in the control group; n=44 completed the study). Participants in the intervention group were given precise instructions on how and when to use the 3 products, and patients in the control group were instructed to continue with their regular skincare regimen.

VECTRA®, a 3-dimensional imaging device, was used to measure improvement in facial erythema, and a red-green-blue color code was used to quantify the intensity of the color red. Lighter shades of red indicated an improvement in facial erythema. The Dermatology Life Quality Index questionnaire was administered to evaluate the impact of rosacea on the participants’ social functioning, psychosocial well-being, and daily activities. In addition, undesirable effects were recorded and product safety was assessed.

Redness was found to be reduced by 16% in the intervention group vs 8% in the control group, from baseline to 8 weeks of treatment. Other rosacea-associated symptoms (eg, itching, dryness) were reduced by 57.1% in the intervention group after 8 weeks of treatment compared with baseline (P ≤.0001), and remained unchanged in the control group.

Quality of life was improved by 54.5% (P =.0149) and 23.8% (nonsignificant) in the intervention and control groups, respectively, from baseline to week 8. The 3 products used in the intervention group were deemed to be safe.

Study strengths include its prospective and controlled design as well as the use of an objective and quantitative method to evaluate facial erythema. Study limitations include a small control group and short treatment period.

“[I]t might be interesting to include a follow-up period in future studies and to elaborate the relevance of this skincare series if complementing a pharmaceutical approach,” noted the study authors.

Disclosures: Several study authors declared affiliations with the pharmaceutical industry. Please see the original reference for a full list of authors’ disclosures.


Guertier A, Jøntvedt NM, Clanner-Engelshofen BM, et al. Efficacy and safety results of micellar water, cream and serum for rosacea in comparison to a control group. J Cosmet Dermatol. doi: 10.1111/JOCD.13591